MedTrace Logo

A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)

NCT01572675 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 547

Last updated 2022-02-09

Study results available
· View outcomes & findings →

Summary

This postmarketing study will examine the use of etoricoxib (Arcoxia®) in routine clinical practice in France as well as the use of celecoxib (Celebrex®).

Conditions

Interventions

DRUG

etorocoxib

Administered as 30 mg or 60 mg oral film-coated tablets

DRUG

celecoxib

Administered as 100 mg or 200 mg oral hard capsules

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2015-03-31
Completion
2015-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01572675 on ClinicalTrials.gov